STUDY QUESTION: Does cord blood androgen level obtained at birth affect the AGD in human newborns?
Introduction
Male reproductive health disorders such as cryptorchidism and hypospadias which manifest at birth or in later adulthood (such as low sperm count and testicular cancer) are remarkably common, and are increasing in incidence (Skakkebaek, 2016) . There is growing evidence that these disorders may be caused by altered diet or exposure to endocrine-disrupting chemicals (EDCs) (Main et al., 2010; Skakkebaek, 2016; van den Driesche et al., 2017) . These disorders together constitute the testicular dysgenesis syndrome (TDS), and may have a common origin in early fetal life due to subtle deficiencies in androgen production or action (Skakkebaek et al., 2001) .
Animal studies have reported a critical time period in early fetal life, termed the masculinization programming window (MPW), during which genital development is programmed, even before morphological differentiation occurs. This MPW is likely to be 8-14 weeks of gestation in humans (Welsh et al., 2008) . Disruption or deficiency of androgen action only during this MPW has been reported to result in TDS disorders, which is reflected as a shortened anogenital distance (AGD). Alteration of testosterone levels after this critical time period had no effect on AGD in rodent models (Drake et al., 2009; van den Driesche et al., 2017; Welsh et al., 2008) .
AGD is an anthropometric measure and has been used to study the effects of prenatal exposure to a variety of EDCs. Thus, AGD has been identified by the US Environmental Protection Agency as a sensitive reproductive endpoint of masculinization and reproductive toxicity studies in animals (Gore et al., 2015) . The hypothesis of in utero androgen disruption and the existence of a MPW and TDS in humans is difficult to prove, especially for conditions that emerge in later life, as it is not possible to look back in time to identify whether in utero fetal testicular dysfunction had occurred in that person. It is also not possible (for ethical reasons) to conduct experimental toxicological studies in humans to study in utero androgen disruption. However, like in animals, if AGD is 'fixed' during early gestation it can serve as a surrogate biomarker of in utero androgen action, specifically during the MPW in humans too. We previously showed that AGD is significantly shorter in term human female infants compared to males , in male infants with undescended testis (Jain and Singal, 2013) , and in boys with hypospadias . Furthermore, AGD has been noted to serve as a potential biomarker for various reproductive health disorders in adult humans (Hsieh et al., 2008 (Hsieh et al., , 2012 Eisenberg et al., 2011; Mendiola et al., 2011; Castano-Vinyals et al., 2012) .
Thus, if a MPW does exist in humans during early gestation, AGD will be permanently fixed by the action of androgens in utero, be significantly longer in males from the MPW onwards, and unaffected by androgen levels after this time period.
Thus, we set out to assess the in-utero androgen action during early gestation by measuring AGD to determine if male preterm and term infants have longer AGD compared to females, and whether AGD and/or other genital anthropometric markers correlate with cord blood androgen levels at birth.
Materials and Methods
In this prospective cohort study, all neonates born at our institute from August 2015 to August 2016 were eligible for inclusion and were randomly selected. Written informed consent from a parent was obtained. Infants born with any genital anomaly, hypospadias, chordee, undescended testis after 32 weeks of gestation, ano-rectal malformation or any known congenital anomalies were excluded from the study. The study was approved by the MetroHealth Institutional Review Board. Gestational age was calculated using antenatal ultrasound at 14-20 weeks, or if not available, Ballard scoring was used. Infant and maternal demographics were retrieved from medical records. Adequate antenatal steroid exposure was defined as receiving two doses of betamethasone administered 24 h apart within 7 days of birth. Weight for gestational age Z score and length for gestational age Z scores were calculated using Fenton growth charts (Fenton and Kim, 2013) .
Measurements
We assessed genital anthropometry which included AGD for both male and female neonates, and stretched penile length (SPL), penile width and girth for males within the first 24 h of life after making sure there was no significant genital swelling on exam. Exam was delayed to 48-72 h of life in very sick preterm infants until clinical stabilization. All the measurements were performed by trained caregivers. Three measurements each were taken for all the measures and the average was used in analysis. Digital Vernier calipers were used which read in increments of 0.01 mm.
For measuring AGD, the infant was put in a supine position with the hips flexed and relaxed laterally. AGD-1 was measured from the center of the anus to the posterior base of scrotum (the junction of the smooth perineal skin and rugated skin of the scrotum) in males (also called AGD-AS (ano-scrotal)) or to the posterior fourchette in females (AGD-AF (anofourchette)). AGD-2 was measured from the center of the anus to the anterior base of the penis (AGD-AP (ano-penile)) in males or to the clitoris in females (AGD-AC (ano-clitoral)) (Fig. 1) .
For measuring SPL, a wooden tongue depressor was used. The tongue depressor was placed at the penopubic junction and held with firm pressure. The penis was gently stretched and held while the foreskin was gently lowered. A mark was then made on the tongue depressor with a fine tip pen corresponding to the tip of the penis. Using Vernier calipers, penile width (diameter) was measured at the mid-shaft of the penis in a flaccid state, while penile glans diameter was measured at the base of the glans of the flaccid penis.
All measurements were performed by three caregivers who underwent a 3-day training period conducted by the author (VJ) before the start of the study. At the end of the training period, 11 term infants (six boys and five girls) with normal genitalia were randomly selected for a reliability study. Three readings were taken for each subject, by each examiner, and reliability analysis was performed. The observer was blinded, and the results were read from the calipers by the accompanying caregiver.
Blood samples and steroid hormone assays
Cord blood was collected at delivery, immediately centrifuged for 15 min at 4°C at 1500g to separate the serum, and the serum was stored at −20°C until analysis. We measured the following sex steroid hormonestotal testosterone, 17-OH progesterone and androstenedione. All serum hormone assays were performed by the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA using liquid chromatography-tandem mass spectrometry or LC-MS/MS, which have been validated and reported previously (Vesper et al., 2009; Bhasin et al., 2011) . The sex steroid hormones were extracted from serum by an online extraction utilizing high throughput liquid chromatography. Extraction and retained analytes were automatically transferred to C-18 analytical columns for conventional liquid chromatography separation followed by MS/ MS analysis on an API 4000 tandem mass spectrometer (Sciex, Foster City, CA, USA) equipped with a heated nebulizer ion source. Intra-assay and inter-assay coefficients of variation were <5%.
Statistical analysis
All statistical analyses were carried out using the Statistical Package for the Social Sciences (SPSS) 22.0 (IBM: Chicago, IL, USA), with significance value set at P = 0.05. Data are represented as mean ± SD or median (25th, 75th percentile) for continuous variables or N (%) for categorical variables, where appropriate. The Student's t test for normally distributed data, Mann-Whitney U test for non-parametric data and Chi Square test for categorical data were used to compare the difference between the sexes. Bivariate associations between genital anthropometric measures and each of the sex steroid hormones were evaluated using the Spearman correlation test. We used multivariate linear regression to analyze the relationship between AGD and sex steroid hormone levels. As all the hormone levels had a skewed distribution, we performed logarithmic transformation on these variables to approximate to normality. A number of confounders based on their importance in the literature and biological plausibility were selected (gestational age, weight for gestational age, length for gestational age, intrauterine growth restriction/small-for-gestational age status, smoke exposure, antenatal steroids, race, maternal age, BMI, hypertension, diabetes and delivery type). When inclusion of a potential covariate resulted in a change in the ß coefficient of <10%, the variable was not retained in the final model. Reference percentile curves for penile anthropometry were computed with the lambda-mu-sigma method (Cole, 2011) . Inter examiner reliability was calculated using intra-class correlation (ICC), using a two-way random model and absolute agreement for single measure.
Results
The study group consisted of 205 infants, of which 117 were males and 88 females. The gestational age ranged between 22 2/7 weeks and 41 weeks with a mean of 35.28 ± 4.7 weeks. Four out of 67 (6%) infants less than 34 weeks did not receive adequate antenatal steroids. The detailed demographics of the study population are shown in Table I . Males were significantly lower in gestational age (mean ± SD; 34.6 ± 4.9 versus 36.1 ± 4.1 weeks, P = 0.04) (Table I) , and had a significantly longer AGD-1 (21.6 ± 6.0 versus 12.7 ± 3.8 mm, P < 0.001) and AGD-2 (41.9 ± 8.7 versus 33.9 ± 7.1 mm, P = 0.004) ( AGD-1 was measured from the center of the anus to the posterior base of scrotum in males or to the posterior fourchette in females. AGD-2 was measured from the center of the anus to the anterior base of the penis in males or to the clitoris in females. AGDi -Anogenital distance index was calculated by AGD dividing the AGD by cube root of birthweight.
(AGDi) for AGD-1 and AGD-2 also showed a significantly longer AGD in males compared to females (both < 0.001, Table II ). The male and female AGDs showed a consistent difference as early as 22 weeks (the lowest gestational age in our study) (Fig. 2) . The umbilical cord serum testosterone levels were significantly higher in males compared to females [median, interquartile range; 13.0 (7.3, 20.5) versus 4.1 (2.5, 5.9), respectively, P < 0.001]. However, there was no difference in levels of 17-OHP (P = 0.697) or androstenedione (P = 0.601) between the two sexes (Table II) . The percentile nomogram charts (3rd, 10th, 50th, 90th, 97th percentile) for penile length, penile girth and glans girth with the gestational age are shown in Fig. 3 . The mean (±SD) of SPL in term infants was 30.38 ± 4.1 mm. There was significant correlation of AGD-1 (r = 0.34, P < 0.001) and AGD-2 (r = 0.29, P = 0.002) with penile length. However, weight adjusted AGD (AGDi) showed no correlation of AGDi-1 (P = 0.28), and AGDi-2 (P = 0.144) with penile length. Similarly, no correlation was seen for penile girth with AGDi-1 (0.084) or AGDi-2 (P = 0.736), and glans girth with AGDi-1 (P = 0.785) or AGDi-2 (P = 0.163).
On univariate analysis, testosterone levels and gestational age were negatively correlated in males (P = 0.004) while the testosterone levels were positively correlated in females (P = 0.001). There was a negative correlation of AGD-2 (P = 0.02) with testosterone levels in males, while in females both AGD-1 (P = 0.003) and AGD-2 (P = 0.018) were positively correlated with testosterone levels (Table III) . No other correlation of any other genital anthropometry measure was seen with any other sex steroid hormone levels. However, on multiple regression analysis after adjusting for potential confounders, none of the AGDs in both males and females correlated with any sex steroid hormonal levels (Table IV) .
The inter-rater reliability using ICC showed almost perfect agreement for the AGD, while it was fair to good for penile anthropometry. ICCs with 95% CI for males were as follows: AGD-1 0.97 (0.84, 0.99), AGD-2 
Discussion
The present study shows that AGD is significantly longer in males compared to females from at least as early as 22 weeks of gestation and AGD is not affected by androgen levels at birth. This result strongly supports the hypothesis of the existence of a MPW in humans during early gestation, during which AGD is fixed by in utero androgen action and is unaffected by androgen levels later in gestation. Thus, AGD serves as biomarker of in utero androgen action during early gestation (likely during the MPW) in humans as well as other species.
AGD has been shown to be a sensitive biomarker of prenatal androgen action in animals. As a result, AGD is being used as a surrogate marker of 'seeing back in time' and to provide a 'lifelong read-out' of the in-utero androgen action in humans. Several human studies have shown a reduced AGD in association with EDCs such as phthalates, bisphenol A and dioxin (Thankamony et al., 2016; Sathyanarayana et al., 2017) . As such, AGD has been associated with multiple human reproductive health outcomes. A shorter AGD in males has been associated with undescended testis, hypospadias, prostate cancer risk and infertility (Jain and Singal, 2013; Thankamony et al., 2016) , while in females a longer AGD has been associated with polycystic ovary syndrome, menstrual cycle irregularities and endometriosis (Mira-Escolano et al., 2014b; Mendiola et al., 2016; Sanchez-Ferrer et al., 2017) . Given the biological importance of this potential marker, it is important to identify whether AGD in humans, as in animals, is set during the MPW and is unaffected by androgens thereafter. (Fowler et al., 2011) measured AGD in electively terminated, normally progressing fetuses from 11 to 20 weeks gestation. They showed that the sex difference in AGD is evident by 11-13 weeks of gestation, and by 17-20 weeks the difference is of the same magnitude as that observed at birth, with a male: female ratio of 2:1, suggesting that the AGD is determined by androgen action during the MPW (i.e. between 8 and 14 weeks of gestation).We confirm the sex difference persists from 22 to 41 weeks of gestation with a similar male: female ratio over the range of the gestational age.
On univariate analysis, we saw a correlation of AGD with testosterone levels. However, after adjusting for gestational age in multivariate analysis this correlation was lost. This suggest that AGD, similar to animals, is influenced by testosterone levels early in gestation (likely during the MPW), but with advancing gestational age AGD becomes independent of the testosterone levels. Human male fetal Leydig cells begin to produce testosterone at around 8 weeks gestation and the production peaks at around 11-14 weeks of gestation -the time period when AGD is fixed during the MPW. Between 12 and 20 weeks, serum testosterone levels in the male fetus are 3 to 8-fold higher than in the females. These testosterone levels then begin to decline, starting at 17-20 weeks of gestation, to levels approaching those seen in females at term birth, and remain low until mini puberty, which happens in males a few months after birth ). The present study corroborates these findings by showing that lower testosterone levels were measured in males with advancing gestational age. However, in spite of this decrease in male fetal testosterone levels the AGD continues to increase later in gestation. In addition, the ratio of male to female AGD remains constant, as observed from 22 weeks of gestation in our study until at least 2 years of age, and does not show any sexual divergence with the decrease in testosterone levels in males during later gestation, or at the time of mini puberty, which predominantly occurs in boys during first few months of life. The rate of body size growth is the same in boys and girls during this period (Thankamony et al., 2009) . Thus, the AGD increase with time relates to body growth rather than to testosterone levels. In addition, insufficient androgen exposure during the MPW results in hypospadias and a shortened AGD (Welsh et al., 2008) . However, as observed in infants Glans Girth (mm) Figure 3 Male genital anthropometry results according to gestational age. Nomogram percentile charts (3rd, 10th, 50th, 90th, 97th percentile) for stretched penile length (A), penile girth (B) and glans girth (C) according to gestational age (Infants with penile length <3 percentile should be evaluated for micropenis.) (n = 118).
at 3 months of age, there is no difference in testosterone levels in those with and without hypospadias, in spite of boys with hypospadias having a shortened AGD (Boisen et al., 2005; . This further strengthens the hypothesis in humans that AGD provides a read-out of in utero androgen action during the MPW and is independent of the postnatal androgen levels. However, in adults, associations of AGD with testosterone levels have been inconclusive. Some studies have shown an association Mira-Escolano et al., 2014a) , while others have not (Parra et al., 2016) . Animal studies have shown that adult rats show a slight degree of plasticity and can be slightly responsive to extreme changes in the androgen environment during pubertal development (Kita et al., 2016; Mitchell et al., 2015) . It is plausible that the AGD fixed during the MPW in humans remains unaffected by androgens thereafter and grows in proportion to body weight, at least until puberty. Further studies on a correlation of AGD with androgen levels in pre-pubertal children will help to further clarify this issue.
We measured umbilical cord androgen levels as they can serve as a marker of perinatal androgen exposure. Cord blood has a unique steroid profile owing to the combination of placental and fetal steroid biosynthesis and metabolism. Thus, due to the presence of a variety of steroid isomers in cord blood, efficient chromatographic discrimination of analytes is particularly important. As such, LC-MS/MS is preferred and has been well validated in cord blood sex steroid hormone measurements (Keelan et al., 2012; Hollier et al., 2014) . In addition, immunoassays are now considered to be suboptimal and inadequate for the measurement of sex steroid hormones where levels are low, such as in children (Handelsman and Wartofsky, 2013; Taylor et al., 2015) . To date only one study has investigated a correlation of AGD with cord blood testosterone levels. Liu et al. measured cord blood testosterone and estradiol using radioimmunoassay in term neonates and found no correlation with AGD (Liu et al., 2016) . We measured the sex steroid hormones using the more sensitive, validated and accurate LC-MS/MS to overcome this shortcoming. In animals, insufficient testosterone production or action during the MPW results in shortened AGD and penile length. However, blockade of androgen action after the MPW, later in gestation, does not affect AGD, but affects the elongation of penis (Welsh et al., 2008; van den Driesche et al., 2017) . We saw a significant correlation of AGD with penile length, but after weight adjusting the AGD (for advancing gestational age) the correlation was lost. This suggests that in humans AGD and penile length have a common influence (testosterone) during early gestation (likely during the MPW). However, later in gestation penile length continues to increase under the influence of testosterone and independent of AGD, which becomes fixed during the MPW. This suggests that if an infant has a normal AGD for gestational age but micropenis at birth the androgen insufficiency probably happened after the MPW (8-14 weeks of gestation). The mean SPL in our study is lower than that previously reported from term infants in the USA (3.05 cm versus 3.50 cm, respectively) (Feldman and Smith, 1975) , possibly due to a different high risk and racially heterogeneous population we serve in our tertiary referral center, but similar to those from UK (3.1 cm) . In term newborns, a SPL < 2 cm (−2.5 SD) is considered as micropenis (Lee et al., 1980) . In our study, micropenis (defined as −2.5 SD of the mean) is also 2 cm in term newborns. Thus, infants with SPL measuring < 3rd percentile for their gestational age in the chart provided should be considered for evaluation for micropenis.
Our study does have its limitations. Our cohort included infants without any congenital genital anomalies. However, we did not collect data on family history of genital malformation, infertility or hormonal disorders, parental EDC exposure or diet pattern, which might have influenced the AGD and/or sex steroid hormone levels in the offspring. This was a single center study with a wide gestational age range. Further larger multi-center studies with a more focused gestational age range can help to confirm the present conclusions. We also did not measure serum estrogen levels, as studies have shown no relationship of AGD with estrogen levels in adult males and females Mira-Escolano et al., 2014a) .
However, the present study does have its strengths. This is the first study, to best of our knowledge, to measure AGD in preterm infants, and as young as 22 weeks of age. All of the measurements were carried out by trained caregivers. We measured both the AGDs used in the literature and carried out a detailed genital anthropometry analysis in preterm infants. We also measured the sex steroid hormones using the validated and sensitive LC-MS/MS method.
To conclude, AGD is significantly longer in preterm and term males compared to females and is not affected by androgen levels at birth, at least from 22 weeks gestation onwards. Our results suggest that AGD in humans, as in animals, is fixed during early gestation (likely during the hypothesized MPW, at 8-14 weeks of gestation) and is unaffected by androgen levels after this critical time period. Thus, AGD may serve as a lifelong biomarker of in utero androgen action during early gestation in humans. As such, the causes of human newborn and adult reproductive health disorders, such as EDCs, should be explored during early gestation. However, further larger and multicenter studies are needed to help corroborate these findings.
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